<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597464</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VCS-2016-02</org_study_id>
    <nct_id>NCT03597464</nct_id>
  </id_info>
  <brief_title>Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin</brief_title>
  <acronym>AURORA2</acronym>
  <official_title>AURORA 2: Aurinia Renal Response in Lupus With Voclosporin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is assess the long-term safety and tolerability of voclosporin
      compared with placebo for up to an additional 24 months following completion of treatment in
      the AURORA 1 study in subjects with lupus nephritis (LN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the Phase 3 continuation study (AURORA 2) is to assess the long-term safety and
      tolerability of voclosporin, added to the standard of care treatment in LN, for an additional
      24 months, following a treatment period of 52 weeks in the AURORA 1 study (AUR-VCS-2016-01).
      All subjects will continue to receive background therapy of MMF and/or oral corticosteroids
      starting at the same dose as at the end of the AURORA 1 study. Subjects with LN, who have
      completed 52 weeks of treatment with study drug in the AURORA 1 study, will be eligible to
      enter the study. The long-term safety and tolerability of the drug combination will be
      assessed from its safety profile while demonstrating the continued ability to achieve and
      maintain long-term renal response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE) profile and routine biochemical and hematological assessments.</measure>
    <time_frame>36 months</time_frame>
    <description>Adverse events (AE) profile and routine biochemical and hematological assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in renal response</measure>
    <time_frame>Months 12, 18, 24, 30 and 36</time_frame>
    <description>Proportion of subject in renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in partial renal response</measure>
    <time_frame>Months 12, 18, 24, 30 and 36</time_frame>
    <description>50% reduction in baseline UPCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal flare as adjudicated by the Clinical Endpoints Committee (CEC).</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Renal flare and extra-renal flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)</measure>
    <time_frame>Months 18, 24 and 36</time_frame>
    <description>Assessment of Systemic Lupus Erythematosus (SLE) Disease Activity within the last 10 days. It scores 24 disease descriptors across 9 organ systems which are summed to a minimum of &lt;2 (considered indicative of no activity) and maximum of 105 points. Scores are weighted and a score of 6 is considered clinically significant. Higher scores indicate worse disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Protein to Creatinine Ratio (UPCR)</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Change from Aurinia Renal Response in Active Lupus With Voclosporin (AURORA) 1 baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Change from AURORA 1 baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine protein</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Change from AURORA 1 baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Change from AURORA 1 baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immunology (Complement 3 (C3)) parameters from AURORA 1 baseline.</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Complement C3: mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immunology parameters (complement 4 (C4)) from AURORA 1 baseline.</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Complement C4: mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immunology parameters (anti-double-stranded deoxyribonucleic acid) from AURORA 1 baseline.</measure>
    <time_frame>Up to 37 months</time_frame>
    <description>Anti-double stranded DNA: IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Health Related Quality of Life Assessments (HRQoL) Short Form Health Survey (SF-36)</measure>
    <time_frame>Months 18,24,30,36</time_frame>
    <description>A set of 36 generic questions assessing quality of life and health status across 8 health concepts (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions) and is reliant upon patient self-reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HRU)</measure>
    <time_frame>Months 12, 15, 18, 21, 24, 27, 30, 33, 36</time_frame>
    <description>Qualitative information gathered form the subjects via interview related to utilisation of healthcare resources e.g visits to health care practitioners</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voclosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin</intervention_name>
    <description>Calcineurin inhibitor, oral, 23.7 mg BID</description>
    <arm_group_label>Voclosporin</arm_group_label>
    <other_name>ISA247</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Voclosporin placebo, oral, 3 capsules BID</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have completed 52 weeks of treatment with study drug in the AURORA 1
             study. Subjects who had a temporary interruption and successfully restarted study drug
             during the AURORA 1 study will be allowed with Medical Monitor approval.

          2. Women of childbearing potential must continue to use effective contraception and have
             a negative urine pregnancy test at Month 12.

          3. Subject is willing to continue taking oral MMF for the duration of the study.

        Exclusion Criteria:

          1. Currently taking or known need for any of the medications or food items listed in
             Section 7.8, Prohibited Therapy and Concomitant Treatment during the study.

          2. Subjects currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or
             expected to require dialysis during the study period.

          3. A planned kidney transplant within study treatment period.

          4. Subjects with any medical condition which, in the Investigator's judgment, may be
             associated with increased risk to the subject or may interfere with study assessments
             or outcomes.

          5. Subjects who are pregnant, breast feeding or, if of childbearing potential, not using
             adequate contraceptive precautions.

          6. Vaccines using live organisms, virus or bacterial, while taking the study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonia Coeshall</last_name>
    <phone>441962715493</phone>
    <email>acoeshall@auriniapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Lisk</last_name>
    <phone>44(0)7790555604</phone>
    <email>llisk@auriniapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AURORA Investigative Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. Review.</citation>
    <PMID>22879439</PMID>
  </reference>
  <reference>
    <citation>Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.</citation>
    <PMID>22087680</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.</citation>
    <PMID>24330024</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8.</citation>
    <PMID>23996158</PMID>
  </reference>
  <reference>
    <citation>Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4.</citation>
    <PMID>23736966</PMID>
  </reference>
  <reference>
    <citation>Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.</citation>
    <PMID>21943027</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus nephritis</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>voclosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

